The Framingham cardiovascular risk score in multiple sclerosis

2015 ◽  
Vol 22 (8) ◽  
pp. 1176-1183 ◽  
Author(s):  
M. Moccia ◽  
R. Lanzillo ◽  
R. Palladino ◽  
G. T. Maniscalco ◽  
A. De Rosa ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cardiovascular Risk ◽  
Risk Score ◽  
Cardiovascular Risk Score

scholarly journals The Framingham cardiovascular risk score and 5‐year progression of multiple sclerosis

2020 ◽  
Author(s):  
Martina Petruzzo ◽  
Antonio Reia ◽  
Giorgia T. Maniscalco ◽  
Fabrizio Luiso ◽  
Roberta Lanzillo ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cardiovascular Risk ◽  
Risk Score ◽  
Cardiovascular Risk Score

scholarly journals Socioeconomic status and cardiovascular risk SCORE

2017 ◽  
pp. 560-565
Author(s):  
Ewa Podolecka ◽  
Agnieszka Doryńska ◽  
Paweł Nadrowski ◽  
Michał Skrzypek ◽  
Magdalena Kwaśniewska ◽  
...  
Keyword(s):  
Socioeconomic Status ◽  
Cardiovascular Risk ◽  
Risk Score ◽  
Cardiovascular Risk Score

scholarly journals What is the best Cardiovascular Risk Score for the Brazilian Population?

2020 ◽  
Vol 33 (6) ◽  
pp. 627-628
Author(s):  
Bruno Ferraz de Oliveira Gomes ◽  
Gláucia Maria Moraes de Oliveira
Keyword(s):  
Cardiovascular Risk ◽  
Risk Score ◽  
Brazilian Population ◽  
Cardiovascular Risk Score

scholarly journals Prior Use of Medication for Primary Prevention in Patients with Coronary Syndrome

2020 ◽  
Vol 11 ◽  
pp. 215013272094694
Author(s):  
Andrés Gaviria-Mendoza ◽  
Julián Andrés Zapata-Carmona ◽  
Andrés Alirio Restrepo-Bastidas ◽  
Carmen Luisa Betancur-Pulgarín ◽  
Jorge Enrique Machado-Alba
Keyword(s):  
Acute Coronary Syndrome ◽  
Cardiovascular Risk ◽  
Primary Prevention ◽  
Risk Score ◽  
High Intensity ◽  
Real Life ◽  
Risk Scores ◽  
Coronary Syndrome ◽  
Cardiovascular Risk Score ◽  
Clinical Records

Background: Cardiovascular disease, especially coronary disease, represents one of the main causes of morbidity and mortality. Objective: To determine the drug prescription profile for primary cardiovascular prevention prior to a first acute coronary syndrome event. Methods: Cross-sectional study. We included adult patients of any sex affiliated with one healthcare insurer of the Colombian Health System, with a diagnosis of a first episode of acute coronary syndrome that occurred during the period of 2015 to 2016. Sociodemographic, clinical and pharmacological variables were evaluated from clinical records. The cardiovascular risk score prior to the event was calculated, and the need for the use of statins and aspirin in primary prevention was defined according to the recommendations of clinical practice guidelines. Results: Clinical records of 322 patients were reviewed with mean age of 61.9 ± 10.8 years, and 77.3% were men. The most frequent comorbidities were dyslipidemia (64.3%), arterial hypertension (62.7%) and diabetes mellitus (30.1%); 22% of the patients were obese, and 33.5% were smokers. The cardiovascular risk score was calculated in 211 patients (65.5%) who had the necessary variables complete. The median 10-year risk according to Framingham risk score was 21.4%, and it was 16.3% according to the American Heart Association. From the 211 patients with risk scores, there were 179 (84.8%) who needed statins (175 of high intensity, 97.8%), and 88 (27.3%) required aspirin as a primary prevention; however, 56 of these patients (31.3%) did not receive any statins, 127 (72.6%) did not receive the high intensity statin they needed, and 38 (43.2% of those with indication) lacked aspirin. Conclusion: Real-life data show that among a group of patients with high cardiovascular risk, a substantial proportion were not receiving medications for primary prevention necessary to reduce their risk and finally suffered an acute coronary event.

Sign in / Sign up

Export Citation Format

Share Document